Kintara Therapeutics (STU:3DMA) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kintara Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kintara Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Kintara Therapeutics's Cash-to-Debt or its related term are showing as below:

STU:3DMA' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.68 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Kintara Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 12.68. And the median was No Debt.

STU:3DMA's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs STU:3DMA: No Debt

Kintara Therapeutics Cash-to-Debt Historical Data

The historical data trend for Kintara Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kintara Therapeutics Cash-to-Debt Chart

Kintara Therapeutics Annual Data

Trend

Dec13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Kintara Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Kintara Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Kintara Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Cash-to-Debt falls into.

Kintara Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kintara Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Kintara Therapeutics had no debt ⁽¹⁾.

Kintara Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Kintara Therapeutics had no debt ⁽¹⁾.

Kintara Therapeutics (STU:3DMA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kintara Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (STU:3DMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

KTRA:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines

Kintara Therapeutics (STU:3DMA) Cash-to-Debt : No Debt (1) (As of Dec. 2023)